

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA124: Pemetrexed for the treatment of non-small-cell lung cancer

This guidance was issued in August 2007 with a review date of January 2010. This review date has been brought forward in order to take account of a recent change in licence.

Background

At the GE meeting on 4th August 2009 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'. That we consult on the proposal.
------------------------------------	----------------------------------------------------------------------------------------------------

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The guidance should be transferred to the 'static guidance list'. Following on from Eli Lilly's consultation response, we further recommend that a text box is included in TA124 to make it clear that the guidance refers to second-line treatment and that there is also guidance on first-line treatment (TA181).
------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Eli Lilly	Disagree	<p>Eli Lilly would prefer that chemotherapy for NSCLC is included within the remit for the lung cancer guideline. They raise the fact that the NICE Lung Cancer Clinical Guideline webpage does not include notification of the post scoping amendment (that 'chemotherapy for NSCLC has been excluded from the remit of the guideline), and request that this information is added to the website, for the sake of consistency.</p> <p>If TA124 is to be transferred to the static the company requests that that:</p> <ul style="list-style-type: none"> • The change to the licensed indication is clearly documented in a prominent position. • The title includes 'second line treatment' to avoid confusion. 	<p>1.1 of the guidance states that "Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer"</p> <p>The guidance document should be amended to include a text box to make it clear that the guidance refers to second-line treatment and that there is also guidance on first-line treatment. The text should read as follows:</p> <div style="border: 1px solid black; padding: 5px; margin: 10px 0;"> <p>NICE technology appraisal guidance 124 (this document) covers the use of pemetrexed as a second-line treatment for locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 181 covers pemetrexed as a first-line treatment for non-small-cell lung cancer (see www.nice.org.uk/TA181).</p> </div> <p>As always prescribers should see the SPC for the full details of the licensed indications.</p>
Sanofi Aventis	Agree		
Roche	Agree		
Research Institute for the Care of Older People (RICE)	No comment		

Respondent	Response to proposal	Details	Comment from Technology Appraisal
National Lung Cancer Forum for Nurses	No comment		
National Public Health Service for Wales	Agree		
Royal College of Nursing	No objection	<i>"...are not aware of any relevant additions to the evidence base that would have a material effect on the guidance"</i>	
Royal College of Pathologists	No objection	<i>"...does not think that there is a need for an earlier review"</i>	
National Cancer Research Institute/ Royal College of Physicians/Royal College of Radiologists/ Association of Cancer Physicians / Joint Collegiate Council for Oncology	Agree		

No response received from:

Consultees	Commentators
<p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern England • Black Health Agency • Breathe Easy • British Lung Foundation • CANCERactive • Cancer Black Care • Cancer Equality • Cancer Voices • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Help the Aged • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • National Council for Palliative Care • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Thoracic Oncology Group • Institute of Cancer Research • MRC CTU - Lung Cancer and Mesothelioma Group • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc <p>National Institute for Health Research Health Technology Assessment Programme</p>

- Tenovus Cancer Information Centre
- United Kingdom Lung Cancer Coalition

Professional groups

- Association of Respiratory Nurse Specialists
- British Association for Services to the Elderly
- British Geriatrics Society
- British Oncological Association
- British Psychosocial Oncology Society
- British Thoracic Society (Lung Cancer and Mesothelioma Working party)
- Cancer Network Pharmacists Forum
- Cancer Research UK
- General Practice Airways Group
- Royal College of General Practitioners
- Royal College of Physicians, Medical Oncology Joint Special Committee
- Royal College of Physicians' Intercollegiate Lung Cancer Group
- Royal Pharmaceutical Society
- Royal Society of Medicine – Intellectual Disabilities Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

Others

- Department of Health
- Welsh Assembly Government
- Shropshire County PCT
- Somerset PCT

Associated Guideline Groups

- National Collaborating Centre for Cancer

GE paper sign-off: Janet Robertson – Associate Director

Contributors to this paper:

Information Specialist: Tom Hudson

Technical Lead: Raphael Yugi

Technical Adviser: Janet Robertson

Project Manager: Adeola Matiluko